3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Colorectal Neoplasms
6
Carcinoma, Hepatocellular
6
Sarcoma
2
Rectal Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Gastrointestinal Stromal Tumors
2
Solid Malignant Tumors
1
Sarcoma, Ewing
1
Recurrence
1
Piebaldism
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Multiple Myeloma
1
Meningioma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Liver Metastasis Colon Cancer
1
HER2 IHC3+ Advanced Colorectal Cancer
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Disease Progression
1
Cholangiocarcinoma
1
Bone Neoplasms
1
Interventions
pasireotide
1
lutetium Lu 177 dotatate
1
lanreotide
1
amino-acid, glucose, and electrolyte solution
1
Sunitinib
1
Octreotide
1
Everolimus
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
regorafenib
×
90 days
×
Clear all
No trials found.